SCHEMBL3710669

SCHEMBL3710669

CC(=O)C1=C(O)C(=O)N(CCc2cccc3ccccc23)C1c1ccc(Br)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
ALDH1A1 P00352 4/20 0.58
RXFP1 Q9HBX9 3/20 0.58
MAPT P10636 2/20 0.58
KDM4E B2RXH2 2/20 0.58
USP7 Q93009 1/20 0.58
HTT P42858 1/20 0.58
TSHR P16473 2/20 0.53
ALOX15 P16050 1/20 0.53
HPGD P15428 1/20 0.52
ATM Q13315 1/20 0.50
TP53 P04637 1/20 0.50
MDM2 Q00987 1/20 0.50
GAA P10253 1/20 0.49
GRIN2C Q14957 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707932 0.92 MEN1 (0.59) MEN1KMT2AALDH1A1RXFP1MAPT
SCHEMBL6781299 0.89 MEN1 (0.68) MEN1KMT2AALDH1A1RXFP1MAPT
SCHEMBL3708650 0.85 USP7 (0.69) MEN1KMT2AALDH1A1RXFP1MAPT
SCHEMBL3706264 0.84 MEN1 (0.60) MEN1KMT2AALDH1A1RXFP1MAPT
SCHEMBL3705340 0.82 MEN1 (0.78) MEN1KMT2AALDH1A1RXFP1MAPT
SCHEMBL3705385 0.81 USP7 (0.79) MEN1KMT2AALDH1A1RXFP1MAPT
SCHEMBL6777293 0.80 KDM4E (0.60) MEN1KMT2AALDH1A1RXFP1MAPT
SCHEMBL3714413 0.79 USP7 (0.73) MEN1KMT2AALDH1A1RXFP1KDM4E
SCHEMBL6784871 0.79 MEN1 (0.54) MEN1KMT2AALDH1A1RXFP1MAPT
SCHEMBL6782306 0.78 KDM4E (0.60) MEN1KMT2AALDH1A1RXFP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed